Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Merck & Co., Inc. — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.93, while Merck & Co., Inc. trades at $132.88 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| FEPI | MRK | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $131.84 |
52-Week Low | $37.98 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI, the REX FANG & Innovation Equity Premium Income ETF, trades at $41.88, showing minimal daily movement with a 0.02% gain. The technical outlook is bullish based on moving averages, though oscillators are neutral. The ETF employs a covered call strategy on a concentrated basket of AI and mega-cap tech stocks, generating a high yield through weekly dividends, with recent payouts around $0.20-$0.21 per share. Recent news highlights its transition to weekly distributions and investor interest due to its aggressive income approach.
FEPI offers a high-yield opportunity through its covered call strategy, appealing for income-focused investors, but faces risks from NAV erosion in downturns and limited upside potential. The concentrated portfolio of volatile tech names increases exposure to sector-specific swings, requiring careful risk assessment for long-term holdings.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
